Updated NCCN guidance recommends starting breast cancer screening at age 35 for women identified as high-risk through AI models or other validated risk assessment tools.
➡️ This signals a broader move toward data-driven, individualized screening pathways.
https://ow.ly/WFjY50YLecm
Managing advanced RCC after adjuvant immunotherapy
In this roundtable discussion, experts explore treatment strategies for patients with disease progression following adjuvant pembrolizumab.
🎥 : https://ow.ly/o2FW50YLe9Q
📊 New global data on childhood cancer survival assess progress toward World Health Organization targets
For pediatric oncology, these findings reinforce the need for continued investment in equitable cancer care worldwide.
➡️ 60% target may not be high enough
https://ow.ly/nI9Z50YLe2e
#ASCOAI: A new perspective from Eddy Saad, MD, MSc of Dana-Farber Cancer Institute, explores how synthetic real-world data can help accelerate clinical trials, improve efficiency, and support better-informed decisions, all while safeguarding patient privacy.
https://ow.ly/zkzg50YJR4E
📢 Advancing treatment options in hepatobiliary cancers
A study highlights that ablative radiotherapy with chemotherapy may improve outcomes in patients with large intrahepatic cholangiocarcinoma.
Led by Ethan Ludmir, MD and Eugene Koay, MD, PhD
Read more: https://ow.ly/BlPt50YJQXq
🫁 Lung cancer isn’t limited to smokers.
New research suggests that a one-time low-dose CT screening may reduce lung cancer mortality among never-smokers in Asia.
Findings presented at hashtag#ELCC26; with commentary from Marina Chiara Garassino, MD
https://ow.ly/QASi50YJQUr
👁️ Phase II CHOPIN trial: Adding nivolumab + ipilimumab to percutaneous hepatic perfusion significantly improved progression-free survival in patients with metastatic uveal melanoma.
🔸 van den Hoek et al
🔗 https://ow.ly/IroH50YuWoW
📢 FDA update: New draft guidance on biosimilar development may streamline testing requirements and reduce development costs—potentially helping expand access to lower-cost biologic medicines.
🔗 ascopost.com/news/march-2026/fda-rele...
🎉 Peter WT Pisters, MD, President of UT MD Anderson Cancer Center was recognized at #SSO2026 with the Charles M. Balch, MD, Distinguished Service Award for advancing surgical oncology through leadership, research, and training.
Read the full article ➡️ https://ow.ly/PHle50Yssax
🖥️ ASCO AI - This week in review:
✔️ FDA-approved AI tool for intraoperative breast cancer margin assessment
✔️ Research on how AI pathology models identify biomarkers
✔️ Deep learning classifier for pediatric brain tumors via liquid biopsy
🎥 Watch now: https://ow.ly/mLaB50YqhE8
🚺 TRAIN-3 evaluates the use of MRI to guide the duration of neoadjuvant chemo in HER2+ breast cancer.
▪️ 3-yr EFS favorable
▪️ Minimizes toxicity
▪️ Preserves QOL
✍️ Gabe Sonke, MD of The Netherlands Cancer Institute
🔗 https://ow.ly/itxX50YoBO4
🌟Introducing the advisory board for ASCO AI in Oncology:
🔹Editor-in-Chief Ravi B. Parikh, MD, MPP, FACP
🔹Kenneth L. Kehl, MD, MPH
🔹Danielle S. Bitterman, MD
🔹Travis Zack, MD, PhD
🔹Jame Abraham, MD, FACP
https://ascoai.org/editorial-advisory-board/
New computational biomarker (TmS) may better predict chemotherapy response in pts with triple-negative breast cancer than current methods; identified high-TmS (favorable) vs low-TmS (poor prognosis) groups.
🔸 Wenyi Wang, PhD | Cell Reports Medicine
Learn more ➡️ https://ow.ly/JXhx50YmrR0
💻 ASCO AI: Can federated learning accelerate precision oncology?
The Cancer AI Alliance is training #AI models across 4 NCI cancer centers—without sacrificing patient privacy.
📝️ Interview with Eliezer Van Allen, MD
🔗 https://ow.ly/N31j50YmEQW
🆕 The February issue of The ASCO Post is LIVE! This issue features: highlights from GI 2026, ASH 2025, ESMOAI 2025; an interview with Kimmie Ng, MD on early-onset GI cancers; perspectives on AML treatment shifts; and MORE!
Read the full issue 👉 https://ascopost.com/issues/february-25-2026/
🧠 New AI deep learning approach (M-PACT) may enable the identification and classification of pediatric brain tumors from a liquid biopsy using cerebrospinal fluid.
✍️ Katie Han & Kyle Smith, PhD of St. Jude Children's Research Hospital | Nature Cancer
🔗 https://ow.ly/Lr5H50Yl51r
📢 Zsofia K. Stadler, MD, has been named the next Editor-in-Chief of JCO Precision Oncology. A leader in cancer genetics and tumor-normal sequencing, she will guide the journal as genomics and AI reshape precision oncology.
🔗 https://ow.ly/m4T250YklUm
🖥️ In advanced pancreatic cancer, a histomorphology-based AI biomarker identified patients more likely to benefit from gemcitabine- vs fluoropyrimidine-based chemo
🩸 Biomarker–treatment interaction significant for TNTD & OS
✍️ Andrew E. Hendifar, MD
🔗 https://ow.ly/LuSg50YiYYM
🫁 #ASCOAI: With gaps in molecular testing rates, AI may expand access to clinical decision-making tools.
Deep-learning models detected EGFR, ALK, BRAF, MET alterations in lung cancer from H&E slides.
👨⚕️ Christian Rolfo, MD, PhD
🔗 https://ow.ly/VLQM50YhS7W
🧠 Early data in glioblastoma: A single injection of a herpes simplex virus triggered sustained antitumor T-cell responses, with immune infiltration linked to clinical benefit.
✍️ Kai Wucherpfennig, MD, PhD & E. Antonio Chiocca, MD, PhD
🔗 https://ow.ly/wM8r50YhGoA
💻 Explore the new ASCO AI in Oncology
Clifford A. Hudis, MD, FACP, FASCO, shares how this new digital hub delivers broad coverage of AI in cancer care—featuring curated AI research, clinical insights, and expert perspectives for oncology professionals.
https://ow.ly/bx5P50Yhg0G
🫀AI meets cardio-oncology. The ONCO-ACS risk model improves prediction of CV death, MI, and ischemic stroke in patients with cancer and heart disease. A step toward more personalized secondary prevention.
Senior author: Thomas F. Lüscher, MD
🔗 https://ow.ly/qVGS50Yfbxq
In an interview with American Society of Clinical Oncology CEO Clifford Hudis, Dr. Hudis introduces ASCO AI in Oncology (ascoai.org), the new digital platform dedicated to understanding how AI is impacting cancer care.
ascoai.org/articles/2026/02/introdu...
📢 ASCO in collaboration with Conexiant today announced the launch of ASCO AI in Oncology (https://ow.ly/tiak50Ycj11 a new digital destination focused on delivering curated content and education around the evolving role of AI in cancer care.
https://ow.ly/WqaG50Ycj10
🏥 American College of Surgeons released its annual National Cancer Database report, showing a major rise in neoadjuvant systemic therapy across cancer types—helping shrink tumors, guiding treatment decisions, & enabling less invasive surgery.
Read key takeaways 👉 https://ow.ly/iqfp50Y8NI7
🗣️ Matthew Strickland, MD, discusses phase IIb TERRIFIC data evaluating neoadjuvant tislelizumab + chemoradiotherapy vs chemo(radio)therapy for patients with locally advanced gastric/GEJ adenocarcinoma.
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
🚨 Cancer workforce shortages threaten patient access & research progress, according to a report from the President’s Cancer Panel.
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🚨 New American Cancer Society study: States that limit/don’t allow short-term health plans saw delays in timely cancer treatment initiation after diagnosis. Health insurance is a major factor in survival. #CancerCare
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
🧠 Targeted therapy shows activity in aggressive meningiomas.
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
🕊️ “A Battle With My Blood” - the final essay by Tatiana Celia Kennedy Schlossberg, recounting her diagnosis with aggressive acute myeloid leukemia and her search for meaning, hope, and memory.
ascopost.com/issues/january-25-2026/a...